MEDICALSYSTEM(SZ:300439) Xin Lang Zheng Quan·2025-10-31 13:01Core Viewpoint - Meikang Bio is a leading company in the in vitro diagnostic field in China, with strong market competitiveness and a diverse range of self-developed products [1] Group 1: Business Performance - In Q3 2025, Meikang Bio reported revenue of 1.136 billion yuan, ranking 8th out of 39 in the industry, surpassing the industry average of 708 million yuan and the median of 330 million yuan, but still significantly behind the top two competitors, New Industries at 3.428 billion yuan and Antu Bio at 3.127 billion yuan [2] - The net profit for the same period was 58.8936 million yuan, ranking 15th out of 39, above the industry median of 26.1892 million yuan but below the industry average of 110 million yuan, with a notable gap from the leaders, Ji'an Medical at 1.588 billion yuan and New Industries at 1.205 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Meikang Bio's debt-to-asset ratio was 19.34%, slightly higher than the previous year's 19.16% and above the industry average of 18.29% [3] - The gross profit margin for Q3 2025 was 39.64%, down from 45.80% in the previous year and below the industry average of 56.20% [3] Group 3: Executive Compensation - Chairman Zou Bingde's compensation for 2024 was 1.7668 million yuan, an increase of 566,800 yuan from 2023 [4] - General Manager Zou Jihua's compensation for 2024 was 869,900 yuan, an increase of 69,800 yuan from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders for Meikang Bio decreased by 6.95% to 23,900, while the average number of circulating A-shares held per shareholder increased by 7.47% to 12,200 [5]